Rapid Micro Biosystems Announces RMBNucleus™ Mold Alarm for the Growth Direct® System
October 10 2022 - 8:30AM
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an
innovative life sciences technology company providing mission
critical automation solutions to facilitate the efficient
manufacturing and fast, safe release of healthcare products, today
announced its newest product, RMBNucleus™ Mold Alarm, which is
designed to rapidly detect environmental molds in the
pharmaceutical manufacturing process. RMBNucleus™ Mold Alarm is
expected to be available on the Growth Direct® System before the
end of 2022.
Slow detection and confirmation of mold contamination continues
to be a critical challenge within environmental monitoring at
pharmaceutical manufacturing facilities and can compromise
products, putting patients at risk. RMBNucleus™ Mold Alarm, a new
software offering for use on the Growth Direct® System, adds rapid
detection allowing for early intervention.
“RMB is committed to supporting life-saving therapies, one
patient at a time,” said Rob Spignesi, President and CEO of Rapid
Micro Biosystems. “We are excited to introduce RMBNucleus™ Mold
Alarm, which will enable our Growth Direct® System to rapidly
detect environmental molds in the pharmaceutical manufacturing
process. As with each of our products on the Growth Direct® System,
RMBNucleus™ Mold Alarm comes with enhanced data integrity and
generates automated alerts at the first sign of mold detection in
as little as one day, allowing for early intervention and reduced
risk of contamination.”
Rapid Micro Biosystems is attending the 2022 PDA Pharmaceutical
Microbiology Conference in Washington, D.C. from October 10-12,
2022. The Company will host an exhibit booth including an
operational Growth Direct® System to demonstrate its rapid
detection technology and the benefits of automation and
digitization in the quality control lab.
Investors and other interested parties are invited to register
to attend the conference at:
https://www.pda.org/global-event-calendar/event-detail/2022-pda-pharmaceutical-microbiology-conference
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology
company providing mission critical automation solutions to
facilitate the efficient manufacturing and fast, safe release of
healthcare products such as biologics, vaccines, cell and gene
therapies, and sterile injectables. The Company’s flagship Growth
Direct® system automates and modernizes the antiquated, manual
microbial quality control (“MQC”) testing workflows used in the
largest and most complex pharmaceutical manufacturing operations
across the globe. The Growth Direct® system brings the quality
control lab to the manufacturing floor, unlocking the power of
in-line/at-the-line MQC automation to deliver faster results,
greater accuracy, increased operational efficiency, better
compliance with data integrity regulations, and quicker decision
making, that customers rely on to ensure safe and consistent supply
of important healthcare products. The Company is headquartered and
has U.S. manufacturing in Lowell, Massachusetts, with global
locations in Lexington, Massachusetts, Switzerland, Germany, and
the Netherlands. For more information, please visit
www.rapidmicrobio.com or follow the company on Twitter at
@rapidmicrobio or on LinkedIn.
Forward Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, but not limited to,
statements regarding the timing for the availability of the
Company’s RMBNucleus™ Mold Alarm; the effectiveness of the
RMBNucleus™ Mold Alarm in the pharmaceutical manufacturing process;
and customer interest in and adoption of the RMBNucleus™ Mold Alarm
software for the Company's Growth Direct System.
In some cases, you can identify forward-looking statements by
terminology such as “outlook,” “aim,” “anticipate,” “assume,”
“believe,” “contemplate,” “continue,” “could,” “due,” “estimate,”
“expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,”
“potential,” “positioned,” “seek,” “should,” “target,” “will,”
“would” and other similar expressions that are predictions of or
indicate future events and future trends, or the negative of these
terms or other comparable terminology, although not all
forward-looking statements contain these words. Forward-looking
statements involve known and unknown risks, uncertainties and
assumptions which may cause actual results to differ materially
from any results expressed or implied by any forward-looking
statement, including, but not limited to, the impact of
macro-economic volatility and COVID-19 and its variants on the
Company’s business and operations, including further delays in
placements and validation of new systems; the Company’s significant
losses since inception; the Company’s ability to meet its publicly
announced guidance and other expectations about its business and
operating results; the Company’s limited experience in marketing
and sales and the effectiveness of its sales processes; the
Company’s need to develop new products and adapt to technological
changes; the Company’s ability to establish and maintain its
position as a leading provider of automated microbial quality
control testing; the Company’s ability to maintain its
manufacturing facility; risks related to third-parties; its ability
to retain key management and other employees; risks related to
regulatory and intellectual property matters; risks related to
supply chain disruptions and the impact of inflation; risks
relation to the exploration of strategic alternatives; and the
other important factors outlined under the caption “Risk Factors”
in the Company’s Annual Report on Form 10-K filed with the
Securities and Exchange Commission (“SEC”) on March 24, 2022, as
such factors may be updated from time to time in its other filings
with the SEC, which are available on the SEC's website at
www.sec.gov and the Investor Relations page of its website at
investors.rapidmicrobio.com. Although the Company believes that the
expectations reflected in its forward-looking statements are
reasonable, it cannot guarantee future results. The Company has no
obligation, and does not undertake any obligation, to update or
revise any forward-looking statement made in this press release to
reflect changes since the date of this press release, except as may
be required by law.
Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
investors@rapidmicrobio.com
Media Contact:
media@rapidmicrobio.com
Rapid Micro Biosystems (NASDAQ:RPID)
Historical Stock Chart
From Jul 2024 to Aug 2024
Rapid Micro Biosystems (NASDAQ:RPID)
Historical Stock Chart
From Aug 2023 to Aug 2024